Volume 88, Issue 3 pp. E59-E66
E-Only: Coronary Artery Disease

Solely abluminal drug release from coronary stents could possibly improve reendothelialization

Haijun Zhang MD

Haijun Zhang MD

Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg Ø, Denmark

Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author
Wei Deng PhD

Wei Deng PhD

Key Laboratory of Public Health Safety, Ministry of Education, School of Public Health, Fudan University, Shanghai, China

Search for more papers by this author
Xiangfei Wang MD

Xiangfei Wang MD

Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author
Shenguo Wang PhD

Shenguo Wang PhD

Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg Ø, Denmark

Institute of Chemistry, Chinese Academy of Sciences, Beijing, China

Search for more papers by this author
Junbo Ge MD

Junbo Ge MD

Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author
Egon Toft MD

Corresponding Author

Egon Toft MD

Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg Ø, Denmark

Biomedical Research Center, College of Medicine, Qatar University, Shareh Jamiaa, Postbox 2716, Doha, Qatar

Correspondence to: Egon Toft, MD, DMSc, F.E.S.C., Biomedical Research Center, College of Medicine, Qatar University, Shareh AIJamiaa, Postbox 2716, Doha, Qatar. E-mail: [email protected]Search for more papers by this author
First published: 10 December 2013
Citations: 9

Conflict of interest: The authors Haijun Zhang, Xiangfei Wang, Shenguo Wang and Junbo Ge contributed to conception and design of the technology. They hold intellectual property rights on the technology, licensed to Rientech Inc., which manufacture stents based on the technology described in the paper. The authors Wei Deng and Egon Toft worked for analysis manuscript critically for important intellectual content.

Abstract

Objectives

To compare a new stent with an asymmetric coating, eluting the drug to the abluminal surface, to a stent with a conventional coating eluting the drug both to the luminal and the abluminal side.

Background

Stents with asymmetric coating, eluting the drug to the vessel wall (BPSES-A), could potentially give faster reendothelialization after percutaneous coronary interventions (PCI) and decrease in in-stent thrombosis and late restenosis.

Methods

BPSES-A, conventional coated stents (BPSES-C), biodegradable polymer stents without drug (BPS, for control), and bare metal stents (BMS, for control) were implanted into the coronary arteries of 38 pigs (75 stents). Pigs were sacrificed after 4, 12, and 24 weeks. Quantitative coronary angiography was used to compare in-stent late lumen loss (LLL) and electron microscopy was used to reveal levels of reendothelialization.

Results

The stents were all successfully implanted. LLL of BPSES-A, BPSES-C, BMS, and BPS were 0.56 ± 0.51, 0.60 ± 0.58, 0.89 ± 0.43, and 1.68 ± 0.30 mm, respectively, after 4 weeks. LLL of BPSES-A and BPSES-C were 0.63 ± 0.53 and 0.69 ± 0.24 mm, respectively, after 12 weeks. LLL of BPSES-A, BPSES-C, and BMS were 0.42 ± 0.15 m, 0.56 ± 0.28 mm, and 0.99 ± 0.13 mm, respectively, after 24 weeks. The scaling of reendothelialization was as follows: after 4 weeks BMS > = BPS > BPSES-A > BPSES-C, after 12 weeks BPSES-A > BPSES-C, and after 24 weeks BMS > BPSES-A > BPSES-C. Reendothelialization was better in BPSES-A than BPSES-C (P < 0.05). There was no correlation between LLL and reendothelialization (P = 0.42).

Conclusion

Asymmetric coating of coronary stents might be helpful to improve reendothelialization. © 2016 Wiley Periodicals, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.